We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

95 hedge funds and large institutions have $123M invested in Cytokinetics in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 28 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

198% more call options, than puts

Call options by funds: $2.99M | Put options by funds: $1M

18% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 28

6% less funds holding

Funds holding: 101 → 95 (-6)

13% less capital invested

Capital invested by funds: $141M → $123M (-$17.7M)

26% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 23

Holders
95
Holders Change
-6
Holders Change %
-5.94%
% of All Funds
2.76%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
33
Reduced
28
Closed
23
Calls
$2.99M
Puts
$1M
Net Calls
+$1.99M
Net Calls Change
-$1.49M

Top Buyers

1
BI
BVF Inc
California
+$4.27M
2
TC
TFS Capital
Pennsylvania
+$2.99M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.2M
4
BA
BlackRock Advisors
Delaware
+$1.77M
5
Deutsche Bank
Deutsche Bank
Germany
+$983K

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$10.9M
2
BIM
Bogle Investment Management
Massachusetts
-$3.38M
3
Millennium Management
Millennium Management
New York
-$2.05M
4
Morgan Stanley
Morgan Stanley
New York
-$802K
5
GACM
Green Arrow Capital Management
New York
-$757K
Name Holding Trade Value Shares
Change 		Change in
Stake
EMG
51
Ellington Management Group
Connecticut
$236K +$238K +36,300 New
NI
52
Numeric Investors
Massachusetts
$234K -$121K -18,384 -34%
SIP
53
Stoneridge Investment Partners
Pennsylvania
$233K +$235K +35,774 New
Charles Schwab
54
Charles Schwab
California
$230K – – –
DS
55
DRW Securities
Illinois
$221K +$145K +22,000 +183%
Two Sigma Investments
56
Two Sigma Investments
New York
$185K -$55.1K -8,388 -23%
KIA
57
Kopp Investment Advisors
Minnesota
$176K -$441K -67,138 -71%
KF
58
Kopp Funds
Wisconsin
$176K +$177K +27,001 New
AQR Capital Management
59
AQR Capital Management
Connecticut
$174K – – –
HCM
60
Highbridge Capital Management
New York
$148K -$147K -22,397 -50%
VOYA Investment Management
61
VOYA Investment Management
Georgia
$144K – – –
Group One Trading
62
Group One Trading
Illinois
$143K +$144K +21,992 New
NFA
63
Nationwide Fund Advisors
Ohio
$135K -$3.04K -462 -2%
TCM
64
Texan Capital Management
Texas
$131K -$5.75K -876 -4%
Bank of America
65
Bank of America
North Carolina
$130K -$85.2K -12,975 -39%
VKH
66
Virtu KCG Holdings
New York
$126K -$45.2K -6,874 -26%
AllianceBernstein
67
AllianceBernstein
Tennessee
$124K -$72.1K -10,971 -36%
AIG
68
American International Group
New York
$115K +$7.03K +1,070 +6%
WS
69
Wedbush Securities
California
$101K +$35.6K +5,418 +54%
D.E. Shaw & Co
70
D.E. Shaw & Co
New York
$99K -$322K -48,944 -76%
GC
71
Guggenheim Capital
Illinois
$82K +$11.1K +1,693 +15%
N
72
Natixis
France
$75K +$74.2K +11,300 New
RhumbLine Advisers
73
RhumbLine Advisers
Massachusetts
$74K +$7.23K +1,100 +11%
CAM
74
CG Asset Management
New York
$67K +$67.3K +10,249 New
Citigroup
75
Citigroup
New York
$63K +$47.3K +7,207 +279%
1 2
3
4 5

CYTK Hedge Fund Activity: Q4 2013 in Review

95 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2013, worth a combined $123M — down 13% from $141M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of CYTK and 17 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 33 added.

The largest buyer was BVF Inc, adding an estimated $4.27M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $10.9M sold.

  • 95 institutional investors held Cytokinetics (CYTK) as of Q4 2013, down from 101 in Q3 2013.
  • Funds reported $123M of Cytokinetics stock for Q4 2013, down 13% quarter-over-quarter.
  • 17 funds opened new Cytokinetics positions in Q4 2013 and 23 closed out, a net change of -6 holders.
  • The largest Cytokinetics buyer in Q4 2013 was BVF Inc, an estimated $4.27M added.
  • The largest Cytokinetics seller in Q4 2013 was T. Rowe Price Associates, an estimated $10.9M sold.

Based on aggregated 13F filings for Q4 2013.